Together, our results indicate the potential for BRCA1 expression as a prognostic biomarker in BC and CRC, suggest tissue-specificity in the impact of loss of BRCA1 expression as related to patient outcomes, and may reveal high levels BRCA1 as a molecular characteristic among younger patients with CRC. This evidence concerns the gene BRCA1 and colorectal carcinoma.